|
1
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Binger DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beier D, Schulz JB and Beier CP:
Chemoresistance of glioblastoma cancer stem cells-much more complex
than expected. Mol Cancer. 10:1282011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mannino M and Chalmers AJ: Radioresistance
of glioma stem cells: Intrinsic characteristic or property of the
‘microenvironment-stem cell unit’? Mol Oncol. 5:374–386. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lathia JD, Mack SC, Mulkearns-Hubert EE,
Valentim CL and Rich JN: Cancer stem cells in glioblastoma. Genes
Dev. 29:1203–1217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohnishi K, Tani T, Bando S, Kubota N,
Fujii Y, Hatano O and Harada H: Plastic induction of
CD133AC133-positive cells in the microenvironment of glioblastoma
spheroid. Int J Oncol. 45:581–586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sutherland RM: Cell and environment
interactions in tumor microregions: The multicell spheroid model.
Science. 240:177–184. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohnishi K, Tani T, Tojo N and Sagara JI:
Glioblastoma cell line shows phenotypes of cancer stem cells in
hypoxic microenvironment of spheroids. Biochem Biophys Res Commun.
546:150–154. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trepel J, Mollapour M, Giaccone G and
Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev
Cancer. 10:537–549. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuno A, Lee MJ, Lee S, Tomita Y, Rekhtman
D, Moore B and Trepel JB: Clinical evaluation and biomarker
profiling of Hsp90 inhibitors. Methods Mol Biol. 1709:423–441.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dote H, Burgan WE, Camphausen K and
Tofilon PJ: Inhibition of hsp90 compromises the DNA damage response
to radiation. Cancer Res. 66:9211–9220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Camphausen K and Tofilon PJ: Inhibition of
Hsp90: A multitarget approach to radiosensitization. Clin Cancer
Res. 13:4326–4330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jhaveri K, Taldone T, Modi S and Chiosis
G: Advances in the clinical development of heat shock protein 90
(Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gaspar N, Sharp SY, Pacey S, Jones C,
Walton M, Vassal G, Eccles S, Pearson A and Workman P: Acquired
resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG,
tanespimycin) in glioblastoma cells. Cancer Res. 69:1966–1975.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Piper PW and Millson SH: Mechanisms of
resistance to Hsp90 inhibitor drugs: A complex mosaic emerges.
Pharmaceuticals (Basel). 4:1400–1422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jarosz D: HSP90: A global regulator of the
genotype-to-phenotype map in cancers. Adv Cancer Res. 129:225–247.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh
DY and Bang YJ: Antitumor activity of NVP-AUY922, a novel heat
shock protein 90 inhibitor, in human gastric cancer cells is
mediated through proteasomal degradation of client proteins. Cancer
Sci. 102:1388–1395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gaspar N, Sharp SY, Eccles SA, Gowan S,
Popov S, Jones C, Pearson A, Vassal G and Workman P: Mechanistic
evalution of the novel HSP90 inhibitor NVP-AUY92 in adult and
pediatric glioblastoma. Mol Cancer Ther. 9:1219–1233. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zaidi S, McLaughlin M, Bhide SA, Eccles
SA, Workman P, Nutting CM, Huddart RA and Harrington KJ: The HSP90
inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous
recombination resulting in mitotic entry with unresolved DNA
damage. PLoS One. 7:e354362012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gandhi N, Wild AT, Chettiar ST, Aziz K,
Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, et
al: Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate
cancer cells. Cancer Biol Ther. 14:347–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hashida S, Yamamoto H, Shien K, Ohtsuka T,
Suzawa K, Maki Y, Furukawa M, Soh J, Asano H, Tsukuda K, et al:
Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of
lung cancer cell lines with acquired resistance to EGFR-tyrosine
kinase inhibitors. Oncol Rep. 33:1499–1504. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie
MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al: Association
of reactive oxygen species levels and radioresistance in cancer
stem cells. Nature. 458:780–783. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Man J, Shoemake JD, Ma T, Rizzo AE, Godley
AR, Wu Q, Mohammadi AM, Bao S, Rich JN and Yu JS: Hyperthermia
sensitizes glioma stem-like cells to radiation by inhibiting AKT
signaling. Cancer Res. 75:1760–1769. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heddleston JM, Li Z, McLendon RE,
Hjelmeland AB and Rich JN: The hypoxic microenvironment maintains
glioblastoma stem cells and promotes reprogramming towards a cancer
stem cell phenotype. Cell Cycle. 8:3274–3284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mao XG, Yan M, Xue XY, Zhang X, Ren HG,
Guo G, Wang P, Zhang W and Huo JL: Overexpression of ZNF217 in
glioblastoma contributes to the maintenance of glioma stem cells
regulated by hypoxia-inducible factors. Lab Invest. 91:1068–1078.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Soeda A, Park M, Lee D, Mintz A,
Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T,
Kassam AB, et al: Hypoxia promotes expansion of the CD133-positive
glioma stem cells through activation of HIF-1alpha. Oncogene.
28:3949–3959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bar EE, Lin A, Mahairaki V, Matsui W and
Eberhart CG: Hypoxia increases the expression of stem-cell markers
and promotes clonogenicity in glioblastoma neurospheres. Am J
Pathol. 177:1491–1502. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Iida H, Suzuki M, Goitsuka R and Ueno H:
Hypoxia induces CD133 expression in human lung cancer cells by
up-regulation of OCT3/4 and SOX2. Int J Oncol. 40:71–79.
2012.PubMed/NCBI
|
|
30
|
Kolenda J, Jensen SS, Aaberg-Jessen C,
Christensen K, Andersen C, Brünner N and Kristensen BW: Effects of
hypoxia on expression of a panel of stem cell and chemoresistance
markers in glioblastoma-derived spheroids. J Neurooncol. 103:43–58.
2011. View Article : Google Scholar : PubMed/NCBI
|
